Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s Zyprexa Protection Strategy: Stress Efficacy, Institutional Market

Executive Summary

Lilly will protect Zyprexa's market share from generic competition by emphasizing the atypical antipsychotic's efficacy and by focusing on the institutional, urgent-need patient market, President and incoming CEO John Lechleiter said during the company's Jan. 29 sales and earnings call

You may also be interested in...



As Risperdal Goes Generic, Antipsychotics Seek To Differentiate Themselves

Johnson & Johnson and other manufacturers of atypical antipsychotics face erosion of their market share with FDA's approval of the first generic version of J&J's Risperdal (risperidone). But they may ward off competition by emphasizing the differences between their products and the first generic among the newer antipsychotics

As Risperdal Goes Generic, Antipsychotics Seek To Differentiate Themselves

Johnson & Johnson and other manufacturers of atypical antipsychotics face erosion of their market share with FDA's approval of the first generic version of J&J's Risperdal (risperidone). But they may ward off competition by emphasizing the differences between their products and the first generic among the newer antipsychotics

Diabetes Draft Guidance May Require Extended Trial Length, Participation

A long-awaited diabetes draft guidance from FDA may result in longer and larger clinical trials, but does not significantly alter the development landscape since it re-affirms the agency's faith in a long-used surrogate marker and the technique of post-market outcomes assessment

Related Content

UsernamePublicRestriction

Register

PS049265

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel